A Phase 1, Multicenter, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single- and Multiple-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4213663 in Healthy Participants, and Two Open-Label, Multiple-Dose Evaluations of LY4213663 in Patients With Rheumatoid Arthritis
Latest Information Update: 16 Jan 2026
At a glance
- Drugs LY 4213663 (Primary) ; LY 4213663 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 12 Dec 2025 Status changed from not yet recruiting to recruiting.
- 11 Dec 2025 New trial record